tbuckley/cabot-search huggingface dataset:
Assessment of Inflammation in an Acute on Chronic Model of Inflammatory Bowel Disease with Ultrasound Molecular Imaging
Authors: Steven Machtaler, Ferdinand Knieling, Richard Luong, Lu Tian, Jürgen K. Willmann
Journal: Theranostics (2015)

Background: Ultrasound (US) molecular imaging has shown promise in assessing inflammation in preclinical, murine models of inflammatory bowel disease.These models, however, initiated acute inflammation on previously normal colons, in contrast to patients where acute exacerbations are often in chronically inflamed regions.In this study, we explored the potential of dual P-and E-selectin targeted US imaging for assessing acute inflammation on a murine quiescent chronic inflammatory background.Methods: Chronic colitis was induced using three cycles of 4% DSS in male FVB mice.Acute inflammation was initiated 2 weeks after the final DSS cycle through rectal administration of 1% TNBS.Mice at different stages of inflammation were imaged using a small animal ultrasound system following i.v.injection of microbubbles targeted to P-and E-selectin.In vivo imaging results were correlated with ex vivo immunofluorescence and histology.Results: Induction of acute inflammation resulted in an increase in the targeted US signal from 5.5 ± 5.1 arbitrary units (a.u.) at day 0 to 61.0 ± 45.2 a.u.(P < 0.0001) at day 1, 36.3 ± 33.1 a.u. at day 3, returning to levels similar to control at day 5. Immunofluorescence showed significant increase in the percentage of P-and E-selectin positive vessels at day 1 (P-selectin: 21.0 ± 7.1% of vessels; P < 0.05; E-selectin: 16.4 ±3.7%; P < 0.05) compared to day 0 (P-selectin: 10.3 ± 5.7%; E-selectin: 7.3 ± 7.0%).Conclusions: Acute inflammation can be accurately measured in a clinically relevant murine model of chronic IBD using ultrasound molecular imaging with a dual P-and E-selectin-targeted contrast agent.
Nocturnal penile tumescence and diagnosis in diabetic impotence
Authors: I Karacan, P J Salis, J C Ware, B Dervent, R L Williams, F B Scott, S L Attia, L E Beutler
Journal: American Journal of Psychiatry (1978)

The authors conducted a study of nocturnal penile tumescence (NPT) in 35 diabetic men, aged 33 to 70, who complained of impotence and in 35 age-matched control subjects. EEGs and other measurements showed that the diabetic men as a group exhibited significant reductions in the total amount of NPT and in the amount and frequency of full erection, thus suggesting that impotence in this cohort was organogenic. Although NPT monitoring represents an advance over the less precise traditional procedures for the differential diagnosis of impotence, the authors stress the need for more research in this area.
Prednisolone was equivalent to indomethacin for pain reduction in acute gout
Authors: Michael Denman
Journal: Annals of Internal Medicine (2016)

Source Citation Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016 Feb 23. [Epub ahead of print] 26903390
Abstract PR06: Nucleation of transcriptional super-enhancers at tumor oncogenes
Authors: Brian J. Abraham, Nicholas Kwiatkowski, Abraham S. Weintraub, Denes Hnisz, Nancy Hannett, Richard A. Young
Journal: Cancer Research (2015)

Abstract Transcriptional super-enhancers drive expression of oncogenes in many cancers and are being targeted with novel transcriptional and epigenetic therapeutics (1,2,3,4). Super-enhancers are acquired in cancers through multiple mechanisms, including DNA translocation of an extant super-enhancer and focal amplification. We recently discovered a novel mechanism by which super-enhancers are nucleated in T cell acute lymphoblastic leukemias (T-ALLs) (5). In this case, a small, monoallelic insertion creates a DNA binding site for a master transcription factor protein, which binds and recruits additional factors to nucleate the super-enhancer, which in turn drives high levels of the TAL1 transcription factor. We describe here a method for unbiased identification of similar genomic insertions that nucleate potentially oncogenic regulatory elements in cancers. This approach uses data from genome-wide ChIP-Seq studies that map locations of enhancer-binding proteins to identify sequences missing from reference genomes. We have found many additional genomic insertions in many additional cancers. I will describe new insights into the regulation of cancer that occur due to nucleation of novel regulatory elements. 1 Hnisz, Abraham, Lee, et al., Cell 2013 2 Loven, Hoke, Lin, et al., Cell 2013 3 Kwiatkowski, et al., Nature, 2014 4 Chipumoro, et al., Cell, 2014 5 Mansour et al., Science 2014 Citation Format: Brian J. Abraham, Nicholas Kwiatkowski, Abraham S. Weintraub, Denes Hnisz, Nancy Hannett, Richard A. Young. Nucleation of transcriptional super-enhancers at tumor oncogenes. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr PR06.
A brief statistical analysis of stomatology papers published in international journals by researchers from the mainland of China
Authors: Yu‐hua Zhang, Yun‐tao Pan, Xiao Hong
Journal: International Journal of Oral Science (2011)

This paper has briefly analyzed the publication status of Chinese stomatology papers in 2009 with statistics from Journal Citation Reports® provided by Thomson Scientific. Only those papers with the first author coming from the mainland of China were included for calculations. We have found a significant increase in the number of SCIE‐indexed papers, most of which were published by six dental institutions in China. Among all Chinese medical institutions, West China School of Stomatology Sichuan University is the first dental institution to enter the top‐20 list with the most publications, and it also ranks the 9th in the number of outstanding articles. West China School of Stomatology Sichuan University and the Forth Military Medical University are the only two dental institutions in China which have published SCIE‐indexed papers over a hundred. The former has published the most SCIE‐indexed stomatology papers, while the latter has the highest average impact factor. As the laboratories and funds in China have close connections with various dental hospitals, the pratice of translational medicine in dentistry is fast and fluent.
Treatment of spontaneous panic attacks with chlomipramine
Authors: S Gloger, L Grunhaus, B Birmacher, T Troudart
Journal: American Journal of Psychiatry (1981)

Recurrent spontaneous panic attacks are psychophysiological symptoms present in panic disorder and agoraphobia with panic attacks. Effective pharmacological treatment for panic attacks is essential to any treatment plan for these conditions. The authors administered chlomipramine to 20 patients who had panic disorder or agoraphobia with panic attacks, and after 8 weeks of treatment 75% of the patients with each diagnosis were asymptomatic. These results support the claim that chlomipramine is highly effective in preventing recurrence of panic attacks.
Development and clinical application of an integrative genomic approach to personalized cancer therapy
Authors: Andrew V. Uzilov, Wei Ding, Marc Y. Fink, Yevgeniy Antipin, Andrew S. Brohl, Claire Davis, Chun Yee Lau, Chetanya Pandya, Hardik Shah, Yumi Kasai, James Powell, Mark Micchelli, Rafael Castellanos, Zhongyang Zhang, Michael Linderman, Yayoi Kinoshita, Micol Zweig, Katie Raustad, Kakit Cheung, Diane Castillo, Melissa Wooten, Imane Bourzgui, Leah C. Newman, Gintaras Deikus, Bino Mathew, Jun Zhu, Benjamin S. Glicksberg, Aye S. Moe, Jun Liao, Lisa Edelmann, Joel T. Dudley, Robert G. Maki, Andrew Kasarskis, Randall F. Holcombe, Milind Mahajan, Ke Hao, Boris Reva, Janina Longtine, Daniela Starcevic, Robert Sebra, Michael J. Donovan, Shuyu Li, Eric E. Schadt, Rong Chen
Journal: Genome Medicine (2016)

Personalized therapy provides the best outcome of cancer care and its implementation in the clinic has been greatly facilitated by recent convergence of enormous progress in basic cancer research, rapid advancement of new tumor profiling technologies, and an expanding compendium of targeted cancer therapeutics.
Soundings: Year of delivery
Authors: Colin Douglas
Journal: BMJ (2005)

Here in the Greater Auchendreich Health Board area, delivery is our watchword (along with—of course—patient focus, transparency, and accountability). Never were our watchwords seen to better advantage than at a well attended public meeting of the board held in the Auchendreich Assembly Rooms last week, devoted solely to showcasing our achievements over the past year, and signalling the start of the NHS Auchendreich Delivery Road Show 2005.

Our flagship pan-Auchendreich IT and telemedicine project marches on apace, despite the successive withdrawal of a series of increasingly unsatisfactory providers from Japan, Taiwan, and England. And we can now announce that every primary care setting (except, sadly, the most remote and rural, the Upper Dreichmuir singlehanded practice) will have access to email within the year.

Our acclaimed Secondary Care Restructuring, Access, and Modernisation strategy enters an exciting phase, with the coordinator post now readvertised. Once appointed, this key player will bring together a new multidisciplinary strategic consensus group, tasked to handle more sensitively than its predecessor the admittedly tricky issues arising from the proposed closure of the obsolete but much loved Vale of Dreich War Memorial Hospital.

While recent board focus on the Secondary Care Restructuring, Access, and Modernisation strategy may have diverted some of our energies from the all-important waiting list initiative, it could be argued that delivering sustainable, accessible, and cost effective acute care solutions will do more in the long term for our waiting lists than an anti-strategic short term cash injection.

Our financial position has been widely misrepresented in the press. We are not, as one hostile local commentator put it, “going broke for the third year running.” The revenue to be released by the Vale of Dreich and other closures has not, it is true, come on stream yet; but our PFI overspend is emphatically not, as frequently described in Dreich Mail and Advertiser, out of control. And although the key post of director of finance has been vacant for longer than might have been ideal, optimism remains that it will be filled soon—or at least well in advance of our next series of Delivery Road Shows, already pencilled in for March 2006.
The Bristol affair
Authors: J. Garrett, W. Savage, R. Cain
Journal: BMJ (1998)

Editor—It was my programme in March 1996 about the Bristol heart surgery tragedy, for Channel 4’s current affairs series Dispatches, that prompted the General Medical Council (GMC) to investigate what, it subsequently became clear, was the medical scandal of the century. Since then I and my colleagues have continued to report on these cases. I wish to reply to Dunn’s allegations about media reporting of the tragedy; I am, presumably, one of those whom he pronounces guilty of “using a sustained stream of biased, misleading, and often inaccurate information.”1

According to Dunn, bereaved parents should direct their grief and anger over the death of their children towards people like me, rather than the surgeons who operated on the children and have since been found guilty of serious professional misconduct. “Shoot the messenger” is the age old response of those who dislike the message.

The Dispatches programme was researched painstakingly over many months to ensure the accuracy of the story it told. Had it been “misleading” or “inaccurate” it would surely have attracted a writ for defamation from one or more of the three doctors who were named. However, no writ followed the original programme or any of the four documentaries and dozens of shorter reports that HTV has produced since.

Dunn complains that the views of the three doctors have received inadequate attention in the media. I have personally written many letters to James Wisheart, Janardin Dhasmana, and John Roylance, seeking to report their views. None of them has taken up my offer, which remains open. Their refusal to contribute notwithstanding, HTV reported the defence they made at the GMC. Interviews with lay supporters—which we have also broadcast—are, ultimately, no substitute for the doctors’ own words.

It is for the GMC to defend its disciplinary practices, but I would point out that only one of the three doctors found guilty of serious professional misconduct, Dr Roylance, has exercised his right to appeal to the Privy Council. If Mr Wisheart or Mr Dhasmana had genuine reason to think that he had been treated “unfairly” by his peers, as Dunn suggests, surely he would have followed suit.

In revealing and reporting this serious lapse by the medical profession, HTV and its colleagues have illuminated an area of life that has been dark for far too long. Dunn should look closer to home for people to blame if the public does not like what we showed them and demands reform.
Urine Fluorescence in Cancer Diagnosis&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: J. H. Hill, M.D.
Journal: JNCI Journal of the National Cancer Institute (1957)

Urine Fluorescence in Cancer Diagnosis Get access J. H. Hill, M.D. J. H. Hill, M.D. Department of Pathology and Oncology, University of Kansas Medical School, Kansas City, Kansas Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 2, February 1957, Pages 335–339, https://doi.org/10.1093/jnci/18.2.335 Published: 01 February 1957 Article history Received: 29 August 1956 Published: 01 February 1957
CHANGING DIETARY HABITS
Authors: B Martin, A Coe
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation
Authors: Jian Zheng, Xudong Huang, Wen Tan, Dianke Yu, Zhongli Du, Jiang Chang, Lixuan Wei, Yaling Han, Chengfeng Wang, Xu Che, Yifeng Zhou, Xiaoping Miao, Guoliang Jiang, Xianjun Yu, Xianghong Yang, Guangwen Cao, Chaohui Zuo, Zhaoshen Li, Chunyou Wang, Siu Tim Cheung, Yongfeng Jia, Xiongwei Zheng, Hongbing Shen, Chen Wu, Dongxin Lin
Journal: Nature Genetics (2016)
Viscera in Sulfonylurea-Treated Diabetics
Authors: K F WELLMAN, S S LAZARUS, B W VOLK
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia
Authors: L E Tune, I Creese, J R Depaulo, P R Slavney, J T Coyle, S H Snyder
Journal: American Journal of Psychiatry (1980)

The authors measured serum neuroleptic levels by radioreceptor assay in 30 schizophrenic patients receiving haloperidol, fluphenazine, chlorpromazine, molindone, thiothixene, or trifluoperazine. Neuroleptic levels were significantly correlated with clinical state, monitored by an abbreviated version of the Present State Examination (the mini-PSE). Poor therapeutic responses were associated with serum levels under 50 ng/ml chlorpromazine equivalents. There was no correlation between neuroleptic dosage and mini-PSE score or between neuroleptic dose and serum neuroleptic levels.
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study
Authors: Elodie Elkaim, Benedicte Neven, Julie Bruneau, Kanako Mitsui-Sekinaka, Aurelie Stanislas, Lucie Heurtier, Carrie L. Lucas, Helen Matthews, Marie-Céline Deau, Svetlana Sharapova, James Curtis, Janine Reichenbach, Catherine Glastre, David A. Parry, Gururaj Arumugakani, Elizabeth McDermott, Sara Sebnem Kilic, Motoi Yamashita, Despina Moshous, Hicham Lamrini, Burkhard Otremba, Andrew Gennery, Tanya Coulter, Isabella Quinti, Jean-Louis Stephan, Vassilios Lougaris, Nicholas Brodszki, Vincent Barlogis, Takaki Asano, Lionel Galicier, David Boutboul, Shigeaki Nonoyama, Andrew Cant, Kohsuke Imai, Capucine Picard, Sergey Nejentsev, Thierry Jo Molina, Michael Lenardo, Sinisa Savic, Marina Cavazzana, Alain Fischer, Anne Durandy, Sven Kracker
Journal: Journal of Allergy and Clinical Immunology (2016)

Activated phosphoinositide 3-kinase δ syndrome (APDS) 2 (p110δ-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85α, p55α, and p50α) of class IA phosphoinositide 3-kinases.We sought to review the clinical, immunologic, and histopathologic phenotypes of APDS2 in a genetically defined international patient cohort.The medical and biological records of 36 patients with genetically diagnosed APDS2 were collected and reviewed.Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features. Growth retardation was frequently noticed (45%). Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) associated with an increased frequency of transitional B cells (93%), and decreased numbers of naive CD4 and naive CD8 cells but increased numbers of CD8 effector/memory T cells were predominant immunologic features. The majority of patients (89%) received immunoglobulin replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2. Five patients died from APDS2-related complications.APDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options.
Beta-blockers, plasma lipids, and coronary heart disease.
Authors: Cruickshank Jm
Journal: Circulation (1990)

High plasma cholesterol concentration is an important coronary heart disease risk factor, particularly in subjects less than 50 years old. Cholesterol is transported mainly by low (LDLs) and high (HDLs) density lipoproteins. High plasma levels of HDL and its apolipoprotein (A-I) are associated with low coronary heart disease risk, and the reverse is true for LDL and its apolipoprotein (B). Plasma levels of very low density lipoproteins (VLDLs) are probably not an independent risk factor, and the situation for plasma triglycerides is unclear. beta-Blockers have no significant effects on plasma concentrations of either total or LDL cholesterol, but HDL plasma concentration is reduced by about 10%, particularly by nonselective beta-blockers. Plasma triglyceride and VLDL concentrations are both raised by beta-blockade. Despite these plasma lipid changes, beta-blockers, by decreasing myocardial oxygen requirements, exhibit marked anti-ischemic properties. beta-Blockers without intrinsic sympathomimetic activity effect a 30% decrease in death from myocardial infarction (MI) in the years after an acute MI. Primary prevention of MI by beta-blockade in hypertensive persons has been well debated and probably exists (although to a lesser extent than secondary prevention) in men, particularly for nonsmokers (for nonselective beta-blockers), and despite any plasma lipid changes. beta-Blockade can inhibit the preatheromatous and atheromatous changes induced by catecholamines in the coronary arteries of animals. beta-blockers may also reduce or slow the following processes: 1) endothelial permeability to lipoproteins; 2) acylcholesterol acyltransferase activity within the arterial wall, thereby preventing cholesterol esterification and deposition in foam cells; 3) LDL precipitation with arterial wall proteoglycans; 4) calcium influx into atheromatous areas; 5) preatheromatous increased endothelial turnover; 6) heart rate; 7) blood velocity and flow disturbances; 8) atheromatous plaque rupture and consequent coronary thrombosis; and 9) platelet activity. Thus, beta-blockers may inhibit atheromatous plaque formation and reduce the likelihood of plaque beta-blockers may inhibit atheromatous plaque formation and reduce the likelihood of plaque rupture, clot formation, and coronary thrombosis.